Skip to main content

Drug Interactions between turmeric and vilazodone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

turmeric vilazodone

Applies to: turmeric and vilazodone

MONITOR: Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation. In vitro data suggest that curcumin, an active constituent of turmeric, may inhibit platelet-activating factor and platelet aggregation. Isolated case reports have also described increases in INR following initiation of turmeric-containing products in patients treated with a vitamin K antagonist such as warfarin. However, pharmacologic effects of turmeric preparations may be highly variable due to inconsistencies in formulation and potency of commercial herbal products.

MANAGEMENT: Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents. Clinical and laboratory observation for hematologic complications is recommended.

References (4)
  1. Heck AM, DeWitt BA, Lukes AL (2000) "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm, 57, 1221-7; quiz 1228-30
  2. Abebe W (2002) "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther, 27, p. 391-401
  3. Yang X, Thomas DP, Zhang X, et al. (2006) "Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation." Arterioscler Thromb Vasc Biol, 26, p. 85-90
  4. New Zealand Medicines and Medical Devices Safety Authority (2022) Medsafe Monitoring Communication: Beware turmeric/curcumin containing products can interact with warfarin. https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp

Drug and food interactions

Moderate

vilazodone food

Applies to: vilazodone

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of vilazodone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of vilazodone. According to the product labeling, vilazodone blood concentrations in the fasted state can be decreased by approximately 50% compared to the fed state, which may result in diminished effectiveness in some patients. The absolute bioavailability of vilazodone is 72% with food. In study subjects, administration with food (high-fat or light meal) increased vilazodone peak plasma concentration (Cmax) by approximately 147% to 160% and systemic exposure (AUC) by approximately 64% to 85%.

MANAGEMENT: Patients receiving vilazodone should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how vilazodone affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Vilazodone should be taken with food. Administration without food may result in inadequate drug concentrations and diminished effectiveness.

References (1)
  1. (2011) "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer